IndustryCompany release

Aptar third-quarter sales rise 6% to $1.02bn as Russia deconsolidation hits earnings

🇺🇸 Aptargroup, Inc. (ATR) · Thu 29 Oct 2026

The packaging and drug-delivery supplier reported 1% core growth in Pharma, or 8% excluding emergency medicine destocking, and raised its quarterly dividend to $0.50.

AptarGroup reported third-quarter results for the period ended 30 September 2026, with sales up 6% to $1.02 billion. Core sales, a measure the company uses to show underlying performance, rose 5%.

In the Pharma business, core sales grew by 1%. Excluding destocking in emergency medicine, the company put Pharma core growth at 8%, which suggests the weakness was concentrated in that segment.

Reported earnings per share were $0.51. The figure was reduced by a $58 million loss linked to the deconsolidation of Aptar's Russian subsidiary, meaning the unit has been removed from the group's consolidated accounts.

For the fourth quarter, Aptar guided adjusted earnings per share to a range of $1.39 to $1.47. The board also raised the quarterly dividend to $0.50.

What it means for your team

  • Teams relying on Aptar for drug-delivery components should note that the company attributes Pharma's soft core growth to emergency medicine destocking rather than broad weakness.
  • Supply-chain and procurement staff may want to check whether any Russia-related sourcing or supply arrangements involve the deconsolidated subsidiary.
  • The source material provided gives no detail on product-level or regional effects, so any impact on specific programmes should be confirmed directly with suppliers.

Company's press release (SEC filing): Aptargroup, Inc. ↗

Article written by VigiEye from the official source (Aptargroup, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →